- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Anchor test.
Displaying page 1 of 1.
EudraCT Number: 2004-001482-17 | Sponsor Protocol Number: F1D-MC-HGKQ(b) | Start Date*: 2004-10-15 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. | ||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004407-39 | Sponsor Protocol Number: IB1001-203 | Start Date*: 2019-09-18 |
Sponsor Name:IntraBio Ltd. | ||
Full Title: Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study. | ||
Medical condition: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004331-71 | Sponsor Protocol Number: IB1001-201 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study | |||||||||||||
Medical condition: Niemann-Pick Disease type C (NPC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005375-16 | Sponsor Protocol Number: A-99-52120-162 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Institut Produits Synthèse (IPSEN) AB | |||||||||||||
Full Title: A PHASE III PROSPECTIVE, MULTI-CENTER, RANDOMISED, EVALUATOR-BLINDED STUDY TO COMPARE NEUROMUSCULAR JUNCTION (NMJ) TARGETED TECHNIQUE FOR DYSPORT INJECTIONS IN UPPER LIMB SPASTICITY POST STROKE OR ... | |||||||||||||
Medical condition: Upper limb spasticity post stroke or traumatic brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000723-40 | Sponsor Protocol Number: 331-201-00148 | Start Date*: 2024-06-13 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder | ||
Medical condition: Irritability Associated With Autism Spectrum Disorder (ASD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004406-25 | Sponsor Protocol Number: IB1001-202 | Start Date*: 2019-05-09 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study. | |||||||||||||
Medical condition: GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000687-33 | Sponsor Protocol Number: HOPE | Start Date*: 2015-11-18 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Randomized placebo-controlled trial to investigate clinical efficacy, anti-inflammatory properties and safety of prednisolone in hand osteoarthritis: a proof-of-concept study | ||
Medical condition: Hand osteoarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000751-42 | Sponsor Protocol Number: D1441C00150 | Start Date*: 2006-04-07 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ... | ||
Medical condition: SCHIZOPHRENIA or BIPOLAR I DISORDER | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000606-37 | Sponsor Protocol Number: MesenSistem-EB | Start Date*: 2017-11-16 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Universitario La Paz | ||
Full Title: Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. | ||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004074-25 | Sponsor Protocol Number: 01KG1204 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Ruhr-Universität Bochum | |||||||||||||
Full Title: Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial | |||||||||||||
Medical condition: Early rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000716-30 | Sponsor Protocol Number: RGL-003-001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000972-40 | Sponsor Protocol Number: IM101-774 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency | |||||||||||||
Medical condition: Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000750-22 | Sponsor Protocol Number: D1441C00112 | Start Date*: 2006-04-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release T... | |||||||||||||
Medical condition: SCHIZOPHRENIA | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002120-24 | Sponsor Protocol Number: OP-104 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multip... | |||||||||||||
Medical condition: Patients with Relapsed or Relapsed-Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000271-32 | Sponsor Protocol Number: W00090GE201 | Start Date*: 2018-11-11 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
Medical condition: BRAF V600E -mutant Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002545-42 | Sponsor Protocol Number: INS-415 | Start Date*: 2021-02-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous M... | |||||||||||||
Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) HU (Completed) AT (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004395-34 | Sponsor Protocol Number: C4221026 | Start Date*: 2022-04-25 | ||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||||||||||||
Full Title: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES | ||||||||||||||||||||||||||||
Medical condition: solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) BE (Ongoing) SK (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001689-41 | Sponsor Protocol Number: RR11/9858 | Start Date*: 2013-11-20 | ||||||||||||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||||||||||||
Full Title: Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness | ||||||||||||||||||||||||||||
Medical condition: Knee osteoarthritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
